Market closed
Cullinan Oncology/$CGEM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cullinan Oncology
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Ticker
$CGEM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
85
Website
CGEM Metrics
BasicAdvanced
$903M
Market cap
-
P/E ratio
-$2.88
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$903M
52-week high
$30.19
52-week low
$7.64
Average daily volume
382K
Financial strength
Current ratio
24.46
Quick ratio
23.884
Long term debt to equity
0.189
Total debt to equity
0.39
Management effectiveness
Return on assets (TTM)
-20.40%
Return on equity (TTM)
-26.53%
Valuation
Price to book
1.45
Price to tangible book (TTM)
1.45
Price to free cash flow (TTM)
-6.121
Growth
Earnings per share change (TTM)
-22.02%
3-year earnings per share growth (CAGR)
33.16%
What the Analysts think about CGEM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cullinan Oncology stock.
CGEM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CGEM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CGEM News
AllArticlesVideos
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
GlobeNewsWire·3 days ago
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
GlobeNewsWire·4 days ago
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cullinan Oncology stock?
Cullinan Oncology (CGEM) has a market cap of $903M as of November 08, 2024.
What is the P/E ratio for Cullinan Oncology stock?
The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of November 08, 2024.
Does Cullinan Oncology stock pay dividends?
No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Cullinan Oncology dividend payment date?
Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.
What is the beta indicator for Cullinan Oncology?
Cullinan Oncology (CGEM) does not currently have a Beta indicator.